NCT Number: NCT00093210
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
The primary objective of this clinical research study is to establish the bioequivalence of 2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Moderate to severe hemophilia B (FIX: C ≤2%)
- Previously treated patients (PTPs) with ≥150 documented exposure days
- Age ≥ 12 years (US sites only)
Exclusion criteria
- Detectable factor IX inhibitor defined as ≥0.6 Bethesda Units for pooled plasma reported by the local laboratory (family history of inhibitors will not exclude the patient)
- Patient history of factor IX inhibitor replacement therapy
- Patient unable to be off factor IX replacement therapy for at least 5 days without bleeding
Treatment and study plan
rFIX-R
DrugInterested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Double-Blind, Randomized, Crossover Evaluation of the Pharmacokinetics of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R); and an Open-Label Safety and Efficacy Evaluation of rFIX-R in Previously Treated Patients With Moderate to Severe (FIX:C≤2%) Hemophilia B
Important dates
- Study completion
- 2005
- First posted
- Oct 7, 2004
- Registry last updated
- Dec 5, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT03938792
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Tampa, Florida, United States
View Trial DetailsLong-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
NCT03307980
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sacramento, California, United States
View Trial DetailsRecombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
NCT06399289
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, Beijing Municipality, China
View Trial DetailsStudy of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Berlin, Germany
View Trial Details